Detail akcie Interpace Biosci Rg online

Business Summary: Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Interpace Biosciences Inc revenues decreased 15% to $29.5M. Net income before extraordinary items decreased 56% to $2.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Molecular Diagnostics and bioinformatics segment income decrease of 50% to $2.5M.